The Ledger

Three drugmakers want a seat in the hospitals’ lawsuit against the 340B rebate pilot, and they came with numbers: $40 million already lost, about $3 million a week, and a $100 billion program. AbbVie, Bristol-Myers Squibb and Boehringer Ingelheim filed a motion to intervene on October 14, and the trade group PhRMA filed its own, per Healthcare Dive, October 19. The 340B Drug Pricing Program lets eligible hospitals and clinics buy outpatient drugs at steep discounts. The pilot is the Department of Health and Human Services (HHS) second attempt to switch that to rebates paid after purchase; hospitals beat the first try in 2025, and HHS announced the revised version in July. Bristol-Myers says it has already lost $40 million to duplicate discounts, Boehringer says about $3 million a week plus more when Medicare’s negotiated price takes effect next year for Ofev and Tradjenta, and AbbVie expects tens of millions. Providers bought $100 billion in 340B drugs last year, up 23%. Who it hits: 340B hospitals, whose cash flow depends on whether they pay full price up front, and manufacturers that want rebates to police duplicate discounts. The article does not name the court or give a hearing date, and we could not open the motions, so this rests on trade reporting. Confidence: High on the filings as reported; Low on whether the court lets the drugmakers in.

A migraine drug developer with Phase 3 results not due until mid-2027 agreed Monday to go public through a blank-check company at about a $600 million equity value. TriGemX Bio and TCGX Acquisition Corp., a special purpose acquisition company (SPAC) listed on Nasdaq, announced a business combination, per the TCGX 8-K press release. A $160 million private placement at $10.00 per share, with Viking Global Investors, ADAR1 Capital Management, BVF Partners, Samsara BioCapital, Vianti Capital and TCGX among the named buyers, plus about $86 million in TCGX’s trust, would bring gross proceeds of about $246 million, assuming no shareholder redemptions. The lead drug, elismetrep, is an oral pill for acute migraine in Phase 3, and both boards have approved. Closing is expected in the first quarter of 2027 and needs shareholder approval at both companies. Who it hits: not providers yet, since approval is years away. It is a read on whether late-stage biotechs can still raise public-market money through a SPAC. Confidence: High on terms (primary filing); Low on how much of the trust survives redemptions.

Two value-based care companies serving safety-net clinics are merging, and they say the combined book covers about 500,000 members and $3 billion in medical spending in 2027. Diverge Health, which works mainly with independent primary care practices, and Medical Home Network (MHN), which works mainly with federally qualified health centers (FQHCs) and Medicaid, announced the merger, per Fierce Healthcare (supplemental; we did not retrieve a company release). The companies expect to work with nearly 100 FQHCs, more than 300 independent practices and more than 20 Medicaid and Medicare payers across nine states in 2027, and Diverge reports a 2% reduction in medical loss ratio from baseline in 2025. Terms were not disclosed. Who it hits: community health centers choosing a vendor for risk contracts, and plans that contract with enablement companies. Confidence: Med on the scale figures, which are company projections; Low on economics, since no price was published.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
TriGemX Bio (SPAC merger, announced October 19)	TCGX Acquisition Corp.	Biotech, migraine drug in Phase 3	About $600 million post-deal equity value; $246 million gross proceeds; close expected Q1 2027	TCGX 8-K
Medical Home Network (merger)	Diverge Health	Value-based care enablement, safety-net clinics	Not disclosed	Fierce Healthcare, supplemental
Invene (reported mid-October)	Carenet Health	Healthcare AI and data consulting	Not disclosed	Pulse 2, supplemental

Scan covered SEC filings, company releases and trade press for October 18 to 20. Larger deals from earlier this week, including the Humana CenterWell joint venture with BlackRock, Galderma’s ZO Skin Health purchase and Gilead’s Vir license, ran in prior issues. We could not confirm several smaller private equity add-ons listed by an aggregator because no company release was found. Elevance Health reports third-quarter results tomorrow.